Monday, August 19, 2019

Drug manufacturers AstraZeneca and Novartis predict challenging future

Drug manufacturers AstraZeneca and Novartis have warned that patent expiries and financial pressure from US health reforms will make for a challenging future. AstraZeneca have...

Coalition announces huge numbers taking cervical cancer vaccine

The coalition Government has announced that more than four million doses of the HPV vaccine which protects against cervical cancer have been administered in...

MHRA sets deadline for pharmacy reaction to homeopathy draft guidance

The Medicines and Healthcare products Regulatory Agency has given pharmacists until February 18 to provide their reaction to its draft guidance concerning the advertising...

Licence extension of arthritis drug offers hope to sufferers of gastric bleeding

Arthritis sufferers were handed a boost when the licence of a popular drug designed to help those with the condition fight fatal gastric bleeding...

Insight Research Group appoints new director

The global marketing research consultancy Insight Research Group has moved to bolster its standing in central Europe with the appointment of Victoria McWade as...

Eisai Ltd opts against pursuing US approval for sepsis drug Eritoran

Japanese drug manufacturer Eisai Ltd has decided not to obtain US approval for a treatment designed to combat severe sepsis because it remains unconvinced...

Swiss researchers claim breast cancer drugs can be used to fight lung cancer

Researchers from the University of Geneva in Switzerland have claimed that drugs used to treat breast cancer can help patients overcome lung cancer. Hope generated...

Teva consolidates position with $1.5 billion unsecured revolving credit facility

Teva Pharmaceutical Industries has consolidated its position as the world's biggest generic drug maker after signing a new three-year $1.5 billion unsecured revolving credit...

Novartis bolsters portfolio with $470 million acquisition of cancer company Genoptix

Swiss drug maker Novartis has bolstered its portfolio with the $470 million acquisition of U.S. cancer diagnostics company Genoptix. The deal highlights Novartis's financial muscle...